Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
What we know about the 'Stranger Things' spinoff — plus the one cast member who guessed it correctly - 2NASA's Artemis 2 astronauts are cruising to the moon. So why are they doing CPR tests today?
- 3Surveys of 6 Hot Savvy Beds
- 4Archaeologists uncover details about the Hjortspring boat's origins
- 5Pulsars to the extreme: Spinning dead stars found blasting radio signals from the 'edge of their magnetic reach'
- Thousands of Walgreens nasal spray bottles recalled. See which ones.
- This is Countdown, CNN’s newsletter covering NASA’s first time sending humans to deep space in over 50 years
- Jamie Dimon warns Iran war could drive inflation, interest rates higher
- RFK Jr.'s handpicked vaccine panel just voted to stop recommending hepatitis B shots for all newborns. Why experts object.
- Signature Scents: A Manual for Outstanding Fragrances
- Figure out How to Pick a Crematorium: Key Contemplations.
- Germany's Merz under fire in Brazil for his comments on Amazon host city of COP30
- IDF strikes Hamas terror base in Lebanon, Health Ministry says 11 killed
- An Ideal Getaway - Spots for Solo Travel
